ACC: American College of Cardiology

Even as virtual care has dropped from the peaks at the beginning of the pandemic, some aspects of it will not go away in cardiology care, said Dipti Itchhaporia, MD, FACC, the 70th president of the American College of Cardiology.

Patients hospitalized for acute heart failure and prescribed empagliflozin saw improvements in quality of life at 15 and 90 days post-discharge. The study may make the case for prescribing SGLT2 inhibitors before patients leave the hospital.

Researchers presented new data on patient characteristics and outcomes seen in the VICTORIA trial of vericiguat.

Experts outlined updates in the use of artificial intelligence, wearable devices, and artificial wombs for cardiac health during a session at the American College of Cardiology (ACC)’s 71st Scientific Sessions.

There is some confusion about the differences between the European and American guidelines on lowering low-density lipoprotein (LDL) cholesterol, but it’s clear that lower is better, said Pam Taub, MD, FACC, professor of medicine, Division of Cardiovascular Medicine, UC San Diego School of Medicine.

The new guidelines also call for better incorporation and addressing of social determinants of health.

Additional analyses from the SCORED trial further highlight sotagliflozin's benefits among patients with type 2 diabetes and chronic kidney disease, regardless of cardiovascular disease presence.

Data underscored the efficacy of mavacamten in reducing eligibility for surgical intervention among patients with obstructive hypertrophic cardiomyopathy (oHCM).

Milind Desai, MD, MBA, director of the Center for Hypertrophic Cardiomyopathy and medical director of the Center for Aortic Diseases, Cleveland Clinic, speaks on therapeutic implications of the VALOR-HCM late-breaking clinical trial findings presented Saturday at the American College of Cardiology's 71st Scientific Session.

New research presented at the American College of Cardiology's 71st Annual Scientific Session & Expo highlights the high costs of heart failure in the United States and the benefits of healthy eating and exercise as preventive measures.

Orly Vardeny, PharmD, MS, core investigator, Center for Care Delivery and Outcomes Research, and associate professor of Medicine, University of Minnesota Medical School, discusses key barriers to access of novel therapies and what sessions she’s looking forward to during the American College of Cardiology's (ACC) 71st Annual Scientific Session.

The American College of Cardiology will host its annual conference beginning Friday, April 1, 2022, both in-person and online.

The study presented during the American College of Cardiology's 70th Scientific Session called for one group of hospitals to receive special audits and guidance aimed at improving care of patients with heart failure.

Sessions, posters, and late-breaking trials at the American College of Cardiology’s 70th Scientific Session offer updates on vericiguat, SGLT2 inhibitors, sacubitril/valsartan, and heart failure therapies still in the pipeline.

There was consistent, and significant, benefit across all categories of ejection fraction—preserved, reduced, and midrange—but especially among those with preserved ejection fraction, noted Deepak L. Bhatt, MD, MPH, Brigham and Women’s Hospital Heart & Vascular Center.

There is a possible link between psychological distress and inflammatory markers in younger patients with a history of cardiovascular (CV) disease, specifically myocardial infarction, said Mariana Garcia, MD, cardiology fellow at Emory University.

Two top cardiologists debated evidence involving one clinical trial for omega-3 fatty acids, with implications for another, the REDUCE-IT study for icosapent ethyl (Vascepa).

Heart failure is clearly syndromic, with several phenotypes, so it will remain challenging to reconcile patient to therapy until these unique phenotypes can be studied, stated Clyde W. Yancy, MD, MSc, of Northwestern University’s Feinberg School of Medicine.

The study looked at dapagliflozin's benefits in the acute illness setting, specifically organ protection, according to Mikhail N. Kosiborod, MD, vice president of Research at Saint Luke's Health System.

The Dapagliflozin in Respiratory Failure in Patients With COVID-19 trial is the first phase 3 study to examine whether this SGLT2 inhibitor, which has proven effective for multiple chronic conditions, might be similarly useful in an acute setting.

Patients with hypertrophic cardiomyopathy (HCM) had symptomatic, functional, and structural biomarker changes over the course of a little more than 6 months, explained Jay Edelberg, MD, PhD, head of Heart Failure and Cardiomyopathy Development at Bristol Myers Squibb.

ADAPTABLE was an opportunity to accomplish a large-scale study in a generalizable manner: directly involve patients, partner with them, and cocreate the program, noted Schuyler Jones, MD, associate professor of medicine at Duke University.

The investigational drug for obstructive hypertrophic cardiomyopathy is in front of FDA, with an approval target date of January 28, 2022.

Results presented at the American College of Cardiology's 70th Scientific Session show most patients prefer a smaller dose and are more likely to stick with it.

Fourteen months after the American College of Cardiology (ACC) switched its 17,000-person meeting to a virtual format on short notice, the meeting will be online May 15-17 for the second year. The 70th Scientific Session will feature 25 late-breaking clinical trials, emphasizing treatment of heart failure and the right aspirin dose for prevention of secondary cardiovascular disease.

We’re going to celebrate and refocus on the science, reflect and share lessons learned from the pandemic, and really engage our audience in discussions that cover care guidelines and nontraditional pathways of care, said Pamela Bowe Morris, MD, chair of ACC.21.

Understanding that there is a third type of heart failure will further our understanding of the disease, noted Clyde W. Yancy, MD, MSc, chief of cardiology and vice dean for diversity and inclusion at Northwestern University's Feinberg School of Medicine.

There is a persistent gap in heart failure care regarding administration of life-saving therapies outlined in clinical practice guidelines and consensus documents, noted James Jacuzzi, MD, of Harvard Medical School and an ACC trustee.

Both studies were featured during the American College of Cardiology's annual briefing on results for consumers. They will be presented during the 70th Scientific Session, which is set for May 15-17, 2021.

The INFINITY trial, presented at the 68th Scientific Session of the American College of Cardiology, tracked hypertension, brain lesions, and gait in groups of older seniors who had their systolic blood pressure managed to either 130 mm Hg or 145 mm Hg. Results showed significant differences in brain lesions between the 2 groups after 3 years.